Relative to YM101 monotherapy, additional Maraviroc not only expanded tumor‐infiltrating CD8+ T cells but also conferred upon these CD8+ T cells the enhanced cytotoxic potential (Figure 7y). Here, CD8A is linked to neoplasm.